EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity

Antonio Farina, Cristina Birzu, Mad-Hélénie Elsensohn, Alberto Picca iD, Sergio Muñiz-Castrillo, Alberto Vogrig iD, Macarena Villagrán-García, Nicolás Lundahl Ciano-Petersen iD, Luca Massacesi, Baptiste Hervier, Sarah Guégan, Nora Kramkimel und 14 weitere

Brain Communications · 02.05.2023 · 5 (3)

DOI: 10.1093/braincomms/fcad169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Communications, online erschienen am 27.05.2023. Verfasst von Antonio Farina und 25 weiteren Autor:innen. Beteiligte Einrichtung: Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Neurological Hospital, Bron 69677, F…. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence nationale de la recherche, LABEX CORTEX, Université Claude Bernard Lyon 1.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While the spectrum of neurological immune checkpoint inhibitor-related adverse events is expanding, patients’ outcomes are not well documented. This study aimed to assess outcomes of neurological immune-related adverse events and to identify prognostic factors. All patients experiencing grade ≥2 neurological immune-related adverse events identified at two clinical networks (French Reference Center for Paraneoplastic Neurological Syndromes, Lyon; and OncoNeuroTox, Paris) over five years were included. Modified Rankin scores were assessed at onset, 6, 12, 18 months, and last visit. A multi-state Markov model was used to estimate the transition rates between minor disability (mRS <3), severe disability (mRS 3-5), and death (mRS 6), over the study period. The state-to-state transition rates were estimated using maximum likelihood and variables were introduced into the different transitions to study their effects. A total of 147 patients were included out of 205 patients with a suspicion of neurological immune-related adverse events. The median age was 65 years (range 20–87) and 87/147 patients (59.2%) were male. Neurological immune-related adverse events involved the peripheral nervous system in 87/147 patients (59.2%), the central nervous system in 51/147 (34.7%), and both systems in 9/147 (6.1%). Paraneoplastic-like syndromes were observed in 30/147 patients (20.4%). Cancers included lung cancers (36.1%), melanoma (30.6%), urological cancers (15.6%), and others (17.8%). Patients were treated with programmed cell death protein (ligan) 1 (PD(L)1) inhibitors (70.1%), CTLA4 inhibitors (3.4%) or both (25.9%). Severe disability was reported in 108/144 patients (75.0%) at onset and in 33/146 patients (22.6%) at last visit (median follow-up duration: 12 months, range 0.5–50); 48/147 (32.7%) patients died, from cancer progression (17/48, 35.4%), neurological toxicity (15/48, 31.2%), other causes (10/48, 20.8%) or unknown causes (6/48, 12.5%). The rate of transition from severe to minor disability independently increased with melanoma [compared to lung cancer, hazard ratio = 3.26, 95%CI (1.27; 8.41)] and myositis/neuromuscular junction disorders [hazard ratio = 8.26, 95%CI (2.90; 23.58)], and decreased with older age [hazard ratio = 0.68, 95%CI (0.47; 0.99)] and paraneoplastic-like syndromes [hazard ratio = 0.29, 95%CI (0.09; 0.98)]. In patients with neurological immune-related adverse events, myositis/neuromuscular junction disorders and melanoma increase the transition rate from severe to minor disability, while older age and paraneoplastic-like syndromes result in poorer neurological outcomes; future studies are needed to optimize the management of such patients.

Schlagwörter

Stichwörter der Autor:innen

cancer immunotherapy complicationsimmune checkpoint inhibitorsneurological immune-related adverse eventsneurotoxicityparaneoplastic neurological syndromes

Autor:innen und Institutionen

  • Reference Centre for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Neurological Hospital, Bron 69677, France.
  • MeLiS - UCBL-CNRS UMR 5284-INSERM U1314, Université Claude Bernard Lyon 1, Lyon 69008, France.
  • Department of Neuroscience, Psychology, Pharmacology and Child Health, University of Florence, Florence 50139, Italy.
  • Department of Neurology 2 Mazarin, Sorbonne University, Brain Institute, INSERM UMR 1127, Groupe Hospitalier Pitié-Salpêtrière, Paris 75013, France.
  • OncoNeuroTox Group, Center for Patients with Neurological Complications of Oncologic Treatments Groupe Hospitalier Pitié-Salpêtrière et Hôpital Percy, Paris 75561, France.
  • Biostatistics-Bioinformatics Department, Public Health Unit. Hospices Civils de Lyon, Lyon 69003, France.

ORCID-Profile: Alberto Picca, Alberto Vogrig, Nicolás Lundahl Ciano-Petersen, Jérôme Honnorat, Bastien Joubert

Förderung

  • Agence nationale de la recherche
  • LABEX CORTEX
  • Université Claude Bernard Lyon 1

Zitieren

APA

Farina, A., Birzu, C., Elsensohn, M. H., Picca, A., Muñiz-Castrillo, S., Vogrig, A., Villagrán-García, M., Ciano-Petersen, N. L., Massacesi, L., Hervier, B., Guégan, S., Kramkimel, N., Vano, Y., Salem, J. E., Allenbach, Y., Maisonobe, T., Assaad, S., Maureille, A., Devic, P., …, & Joubert, B. (2023). Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Communications, 5(3). https://doi.org/10.1093/braincomms/fcad169

Vancouver

Farina A, Birzu C, Elsensohn MH, Picca A, Muñiz-Castrillo S, Vogrig A, et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Communications. 2023;5(3). doi:10.1093/braincomms/fcad169

BibTeX
@article{Farina2023,
  author = {Farina, Antonio and Birzu, Cristina and Elsensohn, Mad-Hélénie and Picca, Alberto and Muñiz-Castrillo, Sergio and Vogrig, Alberto and Villagrán-García, Macarena and Ciano-Petersen, Nicolás Lundahl and Massacesi, Luca and Hervier, Baptiste and Guégan, Sarah and Kramkimel, Nora and Vano, Yann and Salem, Joe Elie and Allenbach, Yves and Maisonobe, Thierry and Assaad, Souad and Maureille, Aurélien and Devic, Perrine and Weiss, Nicolas and Pegat, Antoine and Maucort-Boulch, Delphine and Ricard, Damien and Honnorat, Jérôme and Psimaras, Dimitri and Joubert, Bastien},
  title = {Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity},
  journal = {Brain Communications},
  year = {2023},
  volume = {5},
  number = {3},
  doi = {10.1093/braincomms/fcad169}
}
Kostenlos starten →